Related Experiment Video
Updated: Feb 15, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Established, emerging and elusive molecular targets in the treatment of lung cancer
Jean-Nicolas Gallant1, Christine M Lovly2
1Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Abstract:
Although histological subtype still underlies tumour classification and treatment, the recognition that lung cancer is, largely, a genetic disease has prompted a push to reconfigure cancer taxonomies according to molecular criteria. In this review, we discuss established (e.g. EGFR, ALK, ROS1, and programmed cell death 1/programmed death-ligand 1), emerging (e.g. MET, RET, and NTRK) and elusive (e.g. TP53, KRAS, and MYC) molecular targets in the treatment of lung cancer. We synthesize a large and rapidly growing body of literature regarding the discovery and therapeutic inhibition of these targets in lung cancer. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Insights
Lung cancer is increasingly viewed as a genetic disease, shifting treatment focus to molecular targets. This review covers established, emerging, and elusive molecular targets for lung cancer therapy.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Histological subtype traditionally dictates lung cancer classification and treatment.
- Growing evidence highlights the genetic basis of lung cancer, necessitating molecular reclassification.
- Understanding molecular drivers is crucial for personalized lung cancer therapy.
Purpose of the Study:
- To review established, emerging, and elusive molecular targets in lung cancer treatment.
- To synthesize current literature on the discovery and therapeutic inhibition of these targets.
- To discuss the evolving landscape of molecularly-driven lung cancer therapy.
Main Methods:
- Literature synthesis and review of established and emerging molecular targets.
- Discussion of genetic mutations (e.g., EGFR, ALK, ROS1, MET, RET, NTRK, TP53, KRAS, MYC) and their therapeutic implications.
- Analysis of programmed cell death 1/programmed death-ligand 1 (PD-1/PD-L1) in immunotherapy.
Main Results:
- Identified key molecular targets including EGFR, ALK, ROS1, PD-1/PD-L1, MET, RET, and NTRK.
- Highlighted the significance of 'elusive' targets like TP53, KRAS, and MYC.
- Summarized the progress in developing targeted therapies and immunotherapies for lung cancer.
Conclusions:
- Lung cancer treatment is transitioning towards a molecularly-driven approach.
- Targeted therapies and immunotherapies offer promising avenues for improved patient outcomes.
- Continued research into molecular targets is essential for advancing lung cancer care.
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Emerging Adulthood
Lung Capacity
Introduction Cardiac Emergencies
Molecular Models

